US-based neurotechnology company Precision Neuroscience has partnered with Beth Israel Deaconess Medical Center (BIDMC) to expand clinical research in brain-computer interface (BCI) technology.
BIDMC, a part of the Beth Israel Lahey Health System, is a teaching hospital affiliated with Harvard Medical School.
The collaboration aims to record and analyse brain activity at high resolution in patients undergoing craniotomy procedures and understand how the brain handles complex behaviours.
It will use Precision’s unique technology, the Layer 7 Cortical Interface, an advanced implant that features 1,024 ultra-thin electrodes distributed across a flexible 1.5 cm2 film.
Layer 7 Cortical Interface is an investigational device, designed to conform to the brain’s surface and captures neural activity with a superior level of detail.
Precision Neuroscience chief commercial and clinical officer Jayme Strauss said: “Partnering with world-renowned institutions like BIDMC is central to our mission of advancing the science behind brain-computer interfaces to improve neurological care.
“This collaboration will provide critical neural data to drive the development of transformative therapies and unlock new possibilities for patients with neurological conditions.”
Under the collaboration, Precision will work closely with the BIDMC research team, led by BIDMC epilepsy surgery director Joshua Aronson.
The study will evaluate the performance of the Layer 7 Cortical Interface during planned craniotomy procedures to record neural activity related to specific functional tasks.
The research collaboration builds on Precision’s portfolio of clinical research partnerships with top medical institutions.
The institutions include West Virginia University’s Rockefeller Neuroscience Institute, Mount Sinai Health System, and Perelman School of Medicine at the University of Pennsylvania.
Aronson said: “Gaining insight into the brain’s electrical signals at this level of resolution opens new possibilities for developing precise, individualised treatments.
“We are thrilled to collaborate with Precision Neuroscience to explore how their technology can advance both research and clinical care.”
Last year, Precision raised $93m in a Series C funding round, with plans to raise a total of $150m in this round, with participation from 21 undisclosed investors.
